Podcast: Biosimilar Development - - BioPharm International

ADVERTISEMENT

Podcast: Biosimilar Development


blog comments powered by Disqus


Anjan Selz, cofounder and CEO of Finox Biotech, takes us on the exciting journey from cell bank to Phase III, something that was achieved in just four years for his company’s biosimilar product, Afolia. In this first of three podcasts, Selz notes that Finox Biotech decided very early on that it wanted to move away from the “me too” approach to biosimilars and focus on product differentiation. Selz goes into detail about biosimilar candidate selection using Afolia (a follicle stimulating hormone), as an example, and describes the importance of having a good understanding of the patent landscape. Selz describes Finox’s outsourcing strategies in terms of partner selection—notably, all are based in Western Europe, and also offers insight into creating meaningful relationships in which success is a shared goal. Posted Dec. 2011.

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here